Catalyst Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Catalyst Pharmaceuticals Inc 公司

Catalyst Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司專注於開發和商業化用於治療罕見和難治疾病的一流藥物。其旗艦商業產品是 FIRDAPSE（氨苯吡啶）片劑 10 毫克 (mg)，獲准用於治療成人和 6 至 17 歲兒童的 Lambert-Eaton 肌無力綜合徵 (LEMS)。該公司還將 FYCOMPA（吡侖帕奈）CIII 作爲處方藥進行營銷，可單獨使用或與其他藥物一起使用，用於治療 4 歲及以上癲癇患者的局竈性發作（伴或不伴繼發性全身性癲癇），以及與其他藥物一起使用，用於治療 12 歲及以上癲癇患者的原發性全身性強直陣攣性癲癇。其產品組合還包括 AGAMREE（vamorolone），一種用於治療杜氏肌營養不良症 (DMD) 的 40 mg/ml 口服混懸液。 vamorolone 是一種用於治療 DMD 患者的皮質類固醇藥物。

Catalyst Pharmaceuticals Inc簡介



公司代碼CPRX

公司名稱Catalyst Pharmaceuticals Inc

上市日期Nov 08, 2006

CEOMr. Richard J. (Rich) Daly

員工數量181

證券類型Ordinary Share

年結日Nov 08

公司地址355 Alhambra Circle

城市CORAL GABLES

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編33134

電話13055292522

網址https://catalystpharma.com/

公司代碼CPRX

上市日期Nov 08, 2006

CEOMr. Richard J. (Rich) Daly

Catalyst Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Patrick James Mcenany

Non-Executive Chairman of the Board

4.28M

-4.46%

Dr. Steven R. Miller, Ph.D.

Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

1.06M

+11.58%

Mr. Donald A. Denkhaus

Independent Director

495.08K

--

Dr. David S. Tierney, M.D.

Independent Director

379.62K

+6.75%

Mr. Brian D. Elsbernd, J.D.

Chief Compliance Officer, Chief Legal Officer

271.04K

+43.74%

Mr. Richard J. (Rich) Daly

President, Chief Executive Officer, Director

226.79K

+13.53%

Dr. Gary Ingenito, M.D., Ph.D.

Chief Medical Officer and Regulatory Officer

68.87K

--

Dr. Preethi Sundaram, Ph.D.

Chief Strategy Officer

41.08K

-8.72%

Ms. Molly Harper

Lead Independent Director

6.75K

--

Ms. Tamar Thompson

Independent Director

1.41K

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Patrick James Mcenany

Non-Executive Chairman of the Board

4.28M

-4.46%

Dr. Steven R. Miller, Ph.D.

Executive Vice President, Chief Operating Officer, and Chief Scientific Officer

1.06M

+11.58%

Mr. Donald A. Denkhaus

Independent Director

495.08K

--

Dr. David S. Tierney, M.D.

Independent Director

379.62K

+6.75%

Mr. Brian D. Elsbernd, J.D.

Chief Compliance Officer, Chief Legal Officer

271.04K

+43.74%

Mr. Richard J. (Rich) Daly

President, Chief Executive Officer, Director

226.79K

+13.53%

收入明細

暫無數據

暫無數據

業務

地區

暫無數據

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.25%

The Vanguard Group, Inc.

7.07%

State Street Investment Management (US)

5.21%

McEnany (Patrick James)

3.48%

Renaissance Technologies LLC

2.65%

其他

68.34%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

13.25%

The Vanguard Group, Inc.

7.07%

State Street Investment Management (US)

5.21%

McEnany (Patrick James)

3.48%

Renaissance Technologies LLC

2.65%

其他

68.34%

股東類型

持股股東

佔比

Investment Advisor

45.16%

Investment Advisor/Hedge Fund

25.00%

Hedge Fund

8.17%

Individual Investor

6.16%

Research Firm

5.16%

Pension Fund

1.35%

Bank and Trust

0.49%

Private Equity

0.34%

Family Office

0.16%

其他

8.02%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

691

105.03M

85.46%

-2.39M

2025Q2

680

109.05M

89.10%

-4.69M

2025Q1

693

109.47M

89.76%

-3.79M

2024Q4

658

108.09M

89.06%

-2.57M

2024Q3

628

104.82M

88.36%

-8.18M

2024Q2

597

106.41M

90.13%

-15.99M

2024Q1

590

105.68M

89.66%

-4.79M

2023Q4

569

93.52M

87.71%

-15.08M

2023Q3

548

90.12M

84.55%

-19.61M

2023Q2

542

91.66M

86.51%

-22.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

16.29M

13.31%

-124.58K

-0.76%

Jun 30, 2025

The Vanguard Group, Inc.

8.74M

7.14%

+268.10K

+3.16%

Jun 30, 2025

State Street Investment Management (US)

5.48M

4.48%

-52.05K

-0.94%

Jun 30, 2025

McEnany (Patrick James)

4.28M

3.5%

-200.00K

-4.46%

Jun 09, 2025

Renaissance Technologies LLC

3.25M

2.66%

+295.20K

+9.99%

Jun 30, 2025

Deerfield Management Company, L.P.

2.88M

2.35%

-542.67K

-15.86%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.87M

2.34%

+101.13K

+3.66%

Jun 30, 2025

Fundsmith LLP

2.71M

2.21%

+557.81K

+25.93%

Jun 30, 2025

Morgan Stanley & Co. LLC

2.35M

1.92%

+715.39K

+43.77%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

1.91M

1.56%

-279.90K

-12.80%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

iShares Neuroscience and Healthcare ETF

3.94%

Invesco Biotechnology & Genome ETF

2.64%

Invesco S&P SmallCap Health Care ETF

1.44%

Janus Henderson Small Cap Growth Alpha ETF

1.36%

ETC 6 Meridian Small Cap Equity ETF

1.15%

Invesco S&P SmallCap 600 GARP ETF

1.13%

VictoryShares Small Cap Free Cash Flow ETF

0.96%

Invesco S&P SmallCap 600 Pure Growth ETF

0.9%

First Trust Small Cap US Equity Select ETF

0.9%

SPDR S&P Biotech ETF

0.79%

iShares Neuroscience and Healthcare ETF

佔比3.94%

Invesco Biotechnology & Genome ETF

佔比2.64%

Invesco S&P SmallCap Health Care ETF

佔比1.44%

Janus Henderson Small Cap Growth Alpha ETF

佔比1.36%

ETC 6 Meridian Small Cap Equity ETF

佔比1.15%

Invesco S&P SmallCap 600 GARP ETF

佔比1.13%

VictoryShares Small Cap Free Cash Flow ETF

佔比0.96%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比0.9%

First Trust Small Cap US Equity Select ETF

佔比0.9%

SPDR S&P Biotech ETF

佔比0.79%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據